1724 related articles for article (PubMed ID: 26129684)
21. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough.
Giammanco A; Taormina S; Chiarini A; Dardanoni G; Stefanelli P; Salmaso S; Mastrantonio P
Vaccine; 2003 May; 21(17-18):1924-31. PubMed ID: 12706678
[TBL] [Abstract][Full Text] [Related]
22. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
23. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
[TBL] [Abstract][Full Text] [Related]
24. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
[TBL] [Abstract][Full Text] [Related]
25. Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects.
Subissi L; Rodeghiero C; Martini H; Litzroth A; Huygen K; Leroux-Roels G; Piérard D; Desombere I
Clin Microbiol Infect; 2020 May; 26(5):645.e1-645.e8. PubMed ID: 31610300
[TBL] [Abstract][Full Text] [Related]
26. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
[TBL] [Abstract][Full Text] [Related]
27. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model.
Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M
Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393
[TBL] [Abstract][Full Text] [Related]
28. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.
Hijnen M; Mooi FR; van Gageldonk PG; Hoogerhout P; King AJ; Berbers GA
Infect Immun; 2004 Jul; 72(7):3716-23. PubMed ID: 15213111
[TBL] [Abstract][Full Text] [Related]
29. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
[TBL] [Abstract][Full Text] [Related]
30. Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy.
Kent A; Ladhani SN; Andrews NJ; Matheson M; England A; Miller E; Heath PT;
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27255149
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
Boehm DT; Hall JM; Wong TY; DiVenere AM; Sen-Kilic E; Bevere JR; Bradford SD; Blackwood CB; Elkins CM; DeRoos KA; Gray MC; Cooper CG; Varney ME; Maynard JA; Hewlett EL; Barbier M; Damron FH
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30012638
[No Abstract] [Full Text] [Related]
32. [Immunologic findings in oral pertussis vaccination].
Kurz R; Mayr J; Höfler KH; Falk W; Rosanelli K
Padiatr Padol; 1986; 21(1):53-9. PubMed ID: 2870453
[TBL] [Abstract][Full Text] [Related]
33. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
34. Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin.
Leininger E; Bowen S; Renauld-Mongénie G; Rouse JH; Menozzi FD; Locht C; Heron I; Brennan MJ
J Infect Dis; 1997 Jun; 175(6):1423-31. PubMed ID: 9180182
[TBL] [Abstract][Full Text] [Related]
35. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
[TBL] [Abstract][Full Text] [Related]
36. The epidemiological situation of pertussis in the Federal Republic of Germany.
Finger H; Wirsing von König CH; Tacken A; Wassilak SG
Dev Biol Stand; 1991; 73():343-55. PubMed ID: 1778329
[TBL] [Abstract][Full Text] [Related]
37. [Serological evaluation of Bordetella pertussis infection in adults with prolonged cough].
Sönmez C; Çöplü N; Gözalan A; Yılmaz Ü; Bilekli S; Demirci NY; Biber Ç; Erdoğan Y; Esen B; Çöplü L
Mikrobiyol Bul; 2016 Jul; 50(3):361-70. PubMed ID: 27525392
[TBL] [Abstract][Full Text] [Related]
38. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
[TBL] [Abstract][Full Text] [Related]
39. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
40. Bordetella pertussis iron regulated proteins as potential vaccine components.
Alvarez Hayes J; Erben E; Lamberti Y; Principi G; Maschi F; Ayala M; Rodriguez ME
Vaccine; 2013 Aug; 31(35):3543-8. PubMed ID: 23731630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
